Home » USA Broker Ratings » Exelixis, Inc. – Consenus Indicates Potential 41.8% Upside

Exelixis, Inc. – Consenus Indicates Potential 41.8% Upside

Exelixis, Inc. found using ticker (EXEL) have now 12 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The range between the high target price and low target price is between 45 and 22 and has a mean target at 30.17. Now with the previous closing price of 21.27 this indicates there is a potential upside of 41.8%. The 50 day MA is 21.02 and the 200 day MA is 21.74. The market cap for the company is $6,232m. Visit the company website at: http://www.exelixis.com

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company’s products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. Exelixis, Inc. has collaboration and license agreement with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Merck, Invenra, Inc., StemSynergy Therapeutics, Inc., and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California.